References

1. Schreus HT. (Karl Linser's discovery of heliotherapy of mycosis fungoides). Dermatol Wochenschr 1965; 151:1069-1074.

2. Bloch H. Solartheology, heliotherapy, phototherapy, and biologic effects: a historical overview. J Natl Med Assoc 1990; 82:517-521.

3. Arlett CF, Lowe JE, Harcourt SA, Waugh AP, Cole J, Roza L, Diffey BL, Mori T, Nikaido O, Green MH. Hypersensitivity of human lymphocytes to UV-B and solar irradiation. Cancer Res 1993; 53:609-614.

4. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998; 1:543-551.

5. Tomimori Y, Ikawa Y, Oyaizu N. Ultraviolet-irradiated apoptotic lymphocytes produce interleukin-10 by themselves. Immunol Lett 2000; 71:49-54.

6. Vink AA, Moodycliffe AM, Shreedhar V, Ullrich SE, Roza L, Yarosh DB, Kripke ML. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci U S A 1997; 94:5255-5260.

7. Ullrich SE. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation. Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J Immunol 1994; 152:3410-3416.

8. Alora MB, Fitzpatrick TB, Taylor CR. Total body heliotherapy. Photodermatol Photo-immunol Photomed 1997; 13:178-180.

9. Kim TY, Kripke ML, Ullrich SE. Immunosuppression by factors released from UV-irra-diated epidermal cells: selective effects on the generation of contact and delayed hyper-sensitivity after exposure to UVA or UVB radiation. J Invest Dermatol 1990; 94:26-32.

10. El-Ghorr AA, Pierik F, Norval M. Comparative potency of different UV sources in reducing the density and antigen-presenting capacity of Langerhans cells in C3H mice. Photochem Photobiol 1994; 60:256-261.

11. Avalos-Diaz E, Alvarado-Flores E, Herrera-Esparza R. UV-A irradiation induces transcription of IL-6 and TNF alpha genes in human keratinocytes and dermal fibroblasts. Rev Rhum Engl Ed 1999; 66:13-19.

12. Tokura Y, Seo N, Yagi H, Takigawa M. Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells. Ann N Y Acad Sci 2001; 941:185-193.

13. Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128:931-933.

14. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311 nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135:1377-1380.

15. Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136:748-752.

16. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38:683-689.

17. Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J Am Acad Dermatol 1984; 10:238-245.

18. Roenigk H, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PJ et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95: 198S-205S.

19. Spittle MF. Mycosis fungoides: electron beam therapy in England. Cancer Treat Rep 1979; 63:639-641.

20. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, Sterry W. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin vs. interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92:3578-3581.

21. Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999; 112:3-12.

22. von Kobyletzki G, Heine O, Stephan H, Pieck C, Stucker M, Hoffmann K, Altmeyer P, Mannherz HG. UVA1 irradiation induces deoxyribonuclease dependent apoptosis in cutaneous T-cell lymphoma in vivo. Photodermatol Photoimmunol Photomed 2000; 16:271-277.

23. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, Grether-Beck S, Ruzicka T, Kapp A, Klotz LO, Sies H, Krutmann J. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186:1763-1768.

24. Plettenberg H, Stege H, Megahed M, Ruzicka T, Hosokawa Y, Tsuji T, Morita A, Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 41:47-50.

25. Zane C, Leali C, Airo P, De Panfilis G, Pinton PC. ''High-dose'' UVA1 therapy of widespread plaque-type nodular erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44:629-633.

26. Migita K, Eguchi K, Kawabe Y, Nakamura T, Shirabe S, Tsukada T, Ichinose Y, Nakamura H, Nagataki S. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 1997; 63:583-587.

27. Perrin-Wolff M, Mishal Z, Bertoglio J, Pallardy M. Position 16 of the steroid nucleus modulates glucocorticoid-induced apoptosis at the transcriptional level in murine T-lym-phocytes. Biochem Pharmacol 1996; 52:1469-1476.

28. Bucks DA, McMaster JR, Maibach HI, Guy RH. Bioavailability of topically administered steroids: a ''mass balance'' technique. J Invest Dermatol 1988; 91:29-33.

29. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients (see comments). Arch Dermatol 1998; 134:949-954.

30. Scholtz W. ijber den Einfluss der Röntgenstrahlen auf die Haut in gesundem und krankem Zustand. Arch Derm Syphil 1902; 59:421-449.

31. Goldschmidt H. Radiation therapy of other cutaneous tumors. In: Goldschmidt H., Panizzon R. (eds). Modern Dermatologic Radiation Therapy. Springer, New York, Berlin, Heiddberg 1991: 123-132.

32. Schirren C. Roentgen irradiation at a distance using soft radiation from beryllium- window tubes. J Invest Dermatol 1955; 24:463-467.

33. Goldschmidt H, Lukacs S, Schoefinius HH. Teleroentgen therapy for mycosis fungoides. J Dermatol Surg Oncol 1978; 4:600-605.

34. Wiskemann A, Buck C. Radiotherapy of mycosis fungoides: twenty years of experience with teleroentgen and low-voltage X-ray therapy. J Dermatol Surg Oncol 1978; 4: 606-610.

35. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1057-1076.

36. Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 1999; 85:1985-1995.

Quiros PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, Wilson LD. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1997; 38:1027-1035.

Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43:951-958. Hallahan DE, Griem ML, Griem SF, Medenica M, Soltani K, Lorincz AL, Baron JM. Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up. J Clin Oncol 1988; 6:1177-1183.

Jones G, McLean J, Rosenthal D, Roberts J, Sauder DN. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol 1992; 26:960-967. Kaye FJ, Bunn PJ, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, Parlette H, Anderson M, Sausville E. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790.

Sipos K. Painting treatment of nitrogen mustard in mycosis fungoides. Dermatologica 1965; 130:3-11.

Van Scott E, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer 1973; 32:18-30.

Smith KJ, Smith WJ, Hamilton T, Skelton HG, Graham JS, Okerberg C, Moeller R, Hackley, BE Jr. Histopathologic and immunohistochemical features in human skin after exposure to nitrogen and sulfur mustard. Am J Dermatopathol 1998; 20:22-28. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40:418-425.

Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1031-1056.

Price NM, Deneau DG, Hoppe RT. The treatment of mycosis fungoides with ointment-based mechlorethamine. Arch Dermatol 1982; 118:234-237.

Van Vloten W, Cooijmans AC, Poel J, Meulenbelt J. Concentrations of nitrogen mustard in the air during topical treatment of patients with mycosis fungoides. Br J Dermatol 1993; 128:404-406.

Volden G, Larsen TE. Remissions of mycosis fungoides induced by nitrogen mustard (HN2). Topical treatment and hydration of tumours and plaques with HN2. Topical desensitization to HN2. A clinical and histopathological controlled study. Dermatologica 1978; 156:129-141.

Vonderheid EC, Van SE, Wallner PE, Johnson WC. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep 1979; 63:681-689. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20:416-428. Monk BE, Vollum DI, du VA. Combination topical nitrogen mustard and photoche-motherapy for mycosis fungoides. Clin Exp Dermatol 1984; 9:243-247. du Vivier A, Vollum DI. Photochemotherapy and topical nitrogen mustard in the treatment of mycosis fungoides. Br J Dermatol 1980; 102:319-322.

Zackheim HS. Treatment of mycosis fungoides with topical nitrosourea compounds. Arch Dermatol 1972; 106:177-182.

55. Zackheim HS, Epstein EJ. Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. Arch Dermatol 1975; 111:1564-1570.

56. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 1994; 13:202-206.

57. Zackheim H. Topical mechlorethamine and carmustine for cutaneous T-cell lymphoma. Semin Dermatol 1983; 2:307-318.

58. Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology 1999; 199:102-105.

59. Zackheim, Epstein EJ, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22:802-810.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment